Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SEMA3C

Financiado

Cerrado

Genetic dissection of the SEMA3C Neuropilin 1 signalling pathway in Chronic Kidn...

Genetic dissection of the SEMA3C Neuropilin 1 signalling pathway in Chronic Kidney Disease progression Regardless of the initial insult, human Chronic Kidney Disease (CKD) is characterised by progressive destruction of the renal parenchyma and the loss of functional nephrons. Renal fibrosis is the common end point of CKDs, the hal... ver más

04/09/2018

INSERM

185K€

Presupuesto del proyecto: 185K€

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-09-04

MSCA-IF-2015-EF: Marie Skłodowska-Curie Individual F...

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSERM

185.08K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NEPHSTROM Novel Stromal Cell Therapy for Diabetic Kidney Disease 6M€ Cerrado

MetaboKID Dissecting renal metabolic reprogramming heterogeneity to ta... Cerrado

SAF2017-89782-R COMO MODELAR LA NEFROPATIA DIABETICA: RESTABLECIENDO EL EPIG... 182K€ Cerrado

FibroTarg Targeting kidney fibrosis by a novel myofibroblast specific... Cerrado

RENOIR RENal prOgenItoRs as tools to understand kidney pathophysiol... 2M€ Cerrado

SAF2012-39947-C02-02 MIRNA NANODELIVERY AND RENAL FIBROSIS 105K€ Cerrado

Duración del proyecto: 29 meses Fecha Inicio: 2016-03-18
Fecha Fin: 2018-09-04

Líder del proyecto

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 185K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Regardless of the initial insult, human Chronic Kidney Disease (CKD) is characterised by progressive destruction of the renal parenchyma and the loss of functional nephrons. Renal fibrosis is the common end point of CKDs, the hallmark of which is the deposition of pathological matrix by myofibroblasts. The worldwide incidence of CKD has reached epidemic proportions with an estimated 10-14% of the adult population known to have CKD. A key challenge for medical planning is to better understand the mechanisms of CKD progression in order to target pharmaceutical interventions at the early stages of the disease. Semaphorins are guidance proteins which influence cellular morphology and function, and play important roles in organogenesis and disease. We found that the secreted glycoprotein SEMA3C was upregulated in two mouse models of kidney injury and in prealbuminuric stages of paediatric CKD patients. We also found that its receptor NRP1 was expressed in proliferating extracellular matrix-producing cells during CKD progression. We propose to use genetically engineered mice to investigate the function of the SEMA3C/NRP1 signalling pathway in CKD progression with three major objectives: 1. Investigate whether SEMA3C and its receptor NRP1 promote CKD progression by analysing the levels of surgically-induced renal injury in mice deficient for Sema3C and Nrp1. 2. Provide an improved mechanistic understanding of the disease by using cutting-edge technologies to unravel new signalling events promoting myofibroblast production and microvasculature rearrangement during kidney injury. 3. Assay the use of SEMA3C as a potential biomarker in the diagnosis of CKD and its progression. This work will substantially contribute to our current understanding of the pathophysiology of CKD and open up new directions for the development of novel treatments targeting this disease spectrum.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores